Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of quadrivalent influenza vaccine efficacy and safety in children 6-35 months
2016-004904-74Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Apr 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of quadrivalent influenza vaccine in influenza (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Absolute efficacy against symptomatic influenza due to any circulating seasonal strain. Started Apr 2017; status: completed.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2016-004904-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004904-74.